(Q43182729)

15 November 2017

title

Glatiramer acetate for the treatment of multiple sclerosis: evidence for a dual anti-inflammatory and neuroprotective role (English)

1 reference

15 November 2017

0 references

Roland Liblau

1

1 reference

15 November 2017

publication date

1 December 2009

1 reference

Journal of the Neurological Sciences

15 November 2017

published in

1 reference

15 November 2017

volume

287 Suppl 1

1 reference

15 November 2017

page(s)

S17-23

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2809%2971296-1

15 November 2017

1 reference

Recent advances in genetic analysis of multiple sclerosis: genetic associations and therapeutic implications

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2809%2971296-1

Immunomodulatory treatment strategies in multiple sclerosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2809%2971296-1

Autoimmune concepts of multiple sclerosis as a basis for selective immunotherapy: from pipe dreams to (therapeutic) pipelines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2809%2971296-1

Exacerbations of multiple sclerosis in patients treated with gamma interferon

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2809%2971296-1

New concepts in the immunopathogenesis of multiple sclerosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2809%2971296-1

Suppression of experimental allergic encephalomyelitis by a synthetic polypeptide

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2809%2971296-1

Effect of a synthetic polypeptide (COP 1) on patients with multiple sclerosis and with acute disseminated encephalomeylitis. Preliminary report

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2809%2971296-1

A pilot trial of Cop 1 in exacerbating-remitting multiple sclerosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2809%2971296-1

Effect of treatment with copolymer 1 (Cop-1) on the in vivo and in vitro manifestations of experimental allergic encephalomyelitis (EAE)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2809%2971296-1

Human cellular immune response to copolymer I and myelin basic protein

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2809%2971296-1

Failure of copolymer I to inhibit the human T-cell response to myelin basic protein

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2809%2971296-1

Immunogenic potentials of copolymer I in normal human lymphocytes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2809%2971296-1

Direct binding of myelin basic protein and synthetic copolymer 1 to class II major histocompatibility complex molecules on living antigen-presenting cells--specificity and promiscuity.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2809%2971296-1

Human and murine CD4 T cell reactivity to a complex antigen: recognition of the synthetic random polypeptide glatiramer acetate

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2809%2971296-1

Bystander suppression of experimental autoimmune encephalomyelitis by T cell lines and clones of the Th2 type induced by copolymer 1

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2809%2971296-1

Glatiramer acetate: mechanisms of action in multiple sclerosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2809%2971296-1

Mechanism of action of glatiramer acetate in treatment of multiple sclerosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2809%2971296-1

Mechanism of action of glatiramer acetate in multiple sclerosis and its potential for the development of new applications

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2809%2971296-1

Type II monocytes modulate T cell-mediated central nervous system autoimmune disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2809%2971296-1

Multiple sclerosis: glatiramer acetate inhibits monocyte reactivity in vitro and in vivo

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2809%2971296-1

Type 2 monocyte and microglia differentiation mediated by glatiramer acetate therapy in patients with multiple sclerosis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2809%2971296-1

Glatiramer acetate increases IL-1 receptor antagonist but decreases T cell-induced IL-1beta in human monocytes and multiple sclerosis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2809%2971296-1

Protective effect of the interleukin-1 receptor antagonist (IL-1ra) on experimental allergic encephalomyelitis in rats

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2809%2971296-1

Multiple sclerosis: comparison of copolymer-1- reactive T cell lines from treated and untreated subjects reveals cytokine shift from T helper 1 to T helper 2 cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2809%2971296-1

Glatiramer acetate (Copaxone) induces degenerate, Th2-polarized immune responses in patients with multiple sclerosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2809%2971296-1

Multiple sclerosis: glatiramer acetate induces anti-inflammatory T cells in the cerebrospinal fluid.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2809%2971296-1

Copolymer 1 induces T cells of the T helper type 2 that crossreact with myelin basic protein and suppress experimental autoimmune encephalomyelitis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2809%2971296-1

Glatiramer acetate-specific T cells in the brain express T helper 2/3 cytokines and brain-derived neurotrophic factorin situ

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2809%2971296-1

Glatiramer acetate (Copaxone) therapy induces CD8(+) T cell responses in patients with multiple sclerosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2809%2971296-1

Therapeutic induction of regulatory, cytotoxic CD8+ T cells in multiple sclerosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2809%2971296-1

Regulatory T cells in the control of inflammatory demyelinating diseases of the central nervous system.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2809%2971296-1

IL-2, regulatory T cells, and tolerance

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2809%2971296-1

Regulatory T cell lineage specification by the forkhead transcription factor foxp3

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2809%2971296-1

Control of regulatory T cell lineage commitment and maintenance

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2809%2971296-1

IPEX as a result of mutations in FOXP3

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2809%2971296-1

Induction of CD4+CD25+ regulatory T cells by copolymer-I through activation of transcription factor Foxp3

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2809%2971296-1

Peripheral generation and function of CD4+CD25+ regulatory T cells

7 January 2021

2 references

https://api.crossref.org/works/10.1016%2FS0022-510X%2809%2971296-1

7 January 2021

https://api.crossref.org/works/10.1016%2FS0022-510X%2809%2971296-1

inferred from DOI database lookup

7 January 2021

based on heuristic

Humoral and cellular immune responses to Copolymer 1 in multiple sclerosis patients treated with Copaxone

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2809%2971296-1

Glatiramer acetate-specific T-helper 1- and 2-type cell lines produce BDNF: implications for multiple sclerosis therapy. Brain-derived neurotrophic factor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2809%2971296-1

Secretion of brain-derived neurotrophic factor by glatiramer acetate-reactive T-helper cell lines: Implications for multiple sclerosis therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2809%2971296-1

Glatiramer acetate-reactive T cells produce brain-derived neurotrophic factor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2809%2971296-1

BDNF and gp145trkB in multiple sclerosis brain lesions: neuroprotective interactions between immune and neuronal cells?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2809%2971296-1

The immunomodulator glatiramer acetate augments the expression of neurotrophic factors in brains of experimental autoimmune encephalomyelitis mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2809%2971296-1

Demyelination arrest and remyelination induced by glatiramer acetate treatment of experimental autoimmune encephalomyelitis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2809%2971296-1

Remyelination in multiple sclerosis: a new role for neurotrophins?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2809%2971296-1

TGF-?-treated microglia induce oligodendrocyte precursor cell chemotaxis through the HGF-c-Met pathway

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2809%2971296-1

Therapeutic immunization protects dopaminergic neurons in a mouse model of Parkinson's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2809%2971296-1

Therapeutic vaccine for acute and chronic motor neuron diseases: implications for amyotrophic lateral sclerosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2809%2971296-1

T cell immunity to copolymer 1 confers neuroprotection on the damaged optic nerve: possible therapy for optic neuropathies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2809%2971296-1

10.1016/S0022-510X(09)71296-1

7 January 2021

Identifiers

DOI

1 reference

15 November 2017

1 reference